Clinical research
Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results
On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO
Avadel Pharmaceuticals plc announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for its once-nightly sodium oxybate, FT218.
Allergy Therapeutics plc provides an update on its Grass MATA MPL phase III study, due to start in Autumn 2020.
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks
The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.
PRESS RELEASES